,address1,address2,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Dr. Ying  Luo Ph.D.', 'age': 57, 'title': 'CEO, Pres, Representative Exec. Officer & Chair', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 234625, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
1,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Dr. Kosuke  Tashiro', 'title': 'Co-Founder', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
2,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Dr. Cristin  Print', 'title': 'Co-Founder', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
3,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Dr. Stephen  Charnock-Jones', 'title': 'Co-Founder', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
4,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Prof. Kan-ichiro  Suzuki Ph.D.', 'age': 68, 'title': 'CFO, Exec. Officer & Director', 'yearBorn': 1954, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
5,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Kazuhiro  Kawauchi', 'age': 60, 'title': 'Exec. Officer & Chief Bus. Devel. Officer', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
6,Nihonbashi-Honcho YS Building,3rd Floor 2-2-2 Nihonbashi-Honcho Chuo-ku,Tokyo,103-0023,Japan,81 3 6214 3600,81 3 6214 3668,https://www.gnipharma.com,Biotechnology,Healthcare,"GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.",701,"{'maxAge': 1, 'name': 'Toshiya  Kitagawa', 'title': 'Chief Strategy Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,13.5,13.4,13.4,13.4,13.5,13.4,13.4,13.4,0.0,1.287162,74.44444,140,140,8,0,0,13.3,14.0,110000,103900,653737728,6.55,14.7,0.027985347,10.256,8.5325,0.0,0.0,EUR,-10515681280,0.05865,43434425,47486500,0.055630002,0.07115,483.843,0.027694935,1672444800,1703980800,1688083200,4.111,1370000000,0.18,3:1,1567382400,-0.45,-1.697,FRA,EQUITY,3G6.F,3G6.F,GNI GROUP LTD.,GNI Group Ltd.,1188885600,Europe/Berlin,CEST,7200000,13.4,none,14277999616,300.675,6198000128,1304999936,4.787,5.446,23360000000,5.263,491.931,0.08781,0.12655,14744000000,-2920999936,876000000,4.107,1.343,0.87667,0.26532,0.24152,JPY,
